title: [Effect of Kuanxiong aerosol on coronary heart disease angina patients: a multicenter randomized controlled clinical study].
abstract: OBJECTIVE
  To evaluate the anginal attack-relieving efficacy and safety of Kuanxiong Aerosol (KA) in patients with coronary heart disease (CHD).
  
  
  METHODS
  A total of 780 patients confirmatively diagnosed as CHD angina from November 2011 to December 2012 in 13 medical centers in the mainland area were assigned to 2 groups by blocked randomization, the treatment group (376 cases) and the control group (374 cases). When the angina attacked, patients in the treatment group received sublingual spray three times, 0.6 mL each time, while those in the control group sublingually dissolved Nitroglycerin Tablet (NT), 0.5 mg each tablet. The effective rate of angina relief, efficacy of electrocardiogram (ECG), and the incidence of adverse reactions were observed.
  
  
  RESULTS
  The 3 min and 5 min remission rates of angina attack were 53.72% (202/376) and 94.41% (355/376) in the treatment group, and 47.86% (179/374) and 90.64% (339/374) in the control group. The 95% confidence interval (CI) of the difference between the 2 groups of 3 min and 5 min remission rates of angina attacks were [(-1.84%, 12.32%) and (-1.33%, 6.85%) respectively, P > 0.05]. The total improvement rates of ST-T changes in the treatment group and the control group after treatment were 74.07% and 73.13% respectively (P > 0.05). The adverse reaction rate was 9.31 (35/376 cases) in the treatment group and 22.46% (84/374 cases) in the control group (P < 0.01).
  
  
  CONCLUSIONS
  KA was not inferior to NT in relieving anginal attacks and improving ischemic ECG changes, and had obviously less adverse reaction.
authors.forename: Li-Zhi
authors.initials: LZ
authors.lastname: Li
authors.forename: Guo-Ju
authors.initials: GJ
authors.lastname: Dong
authors.forename: Chang-Jiang
authors.initials: CJ
authors.lastname: Ge
authors.forename: Jing-Min
authors.initials: JM
authors.lastname: Zhou
authors.forename: Li
authors.initials: L
authors.lastname: Huang
authors.forename: Yan
authors.initials: Y
authors.lastname: He
authors.forename: Jun
authors.initials: J
authors.lastname: Wang
authors.forename: Ai-Hua
authors.initials: AH
authors.lastname: Ren
authors.forename: Zhao-Quan
authors.initials: ZQ
authors.lastname: Huang
authors.forename: Guang-Li
authors.initials: GL
authors.lastname: Zhu
authors.forename: Shu
authors.initials: S
authors.lastname: Lu
authors.forename: Shang-Quan
authors.initials: SQ
authors.lastname: Xiong
authors.forename: Shao-Xiang
authors.initials: SX
authors.lastname: Xian
authors.forename: Zhi-Jun
authors.initials: ZJ
authors.lastname: Zhu
authors.forename: Da-Zhuo
authors.initials: DZ
authors.lastname: Shi
authors.forename: Shu
authors.initials: S
authors.lastname: Lu
authors.forename: Ke-Ji
authors.initials: KJ
authors.lastname: Chen
mesh_terms: D000368:Aged; D000787:Angina Pectoris / Q000188:drug therapy*; D003327:Coronary Disease / Q000188:drug therapy; D004338:Drug Combinations; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009822:Oils, Volatile / Q000627:therapeutic use*; D008517:Phytotherapy
chemical_list: D004338:Drug Combinations; D004365:Drugs, Chinese Herbal; D009822:Oils, Volatile; C037888:Kuan-Xiong